Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68071-4897

5 FDA label images from Nucare Pharmaceuticals,inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68071-4897). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 4897 3)

Pdp (68071 4897 3)
Label for Venlafaxine Hydrochloride 75 mg extended-release capsules from NuCare Pharmaceuticals, Inc. The label indicates a package count of 30 capsules with prescription-only status. It includes manufacturing, lot, and expiration details, storage temperature instructions (68-77°F), and warnings to keep out of reach of children.*
FDA Label Image

Figure 1: Effect Of Interacting Drugs On The Pharmacokinetics Of Venlafaxine And Active Metabolite O-desmethylvenlafaxine (odv). (Venlafaxine Fig1)

Figure 1: Effect Of Interacting Drugs On The Pharmacokinetics Of Venlafaxine And Active Metabolite O-desmethylvenlafaxine (odv). (Venlafaxine Fig1)
A chart depicting pharmacokinetic (PK) fold changes and 90% confidence interval recommendations for venlafaxine when administered with various interacting drugs including ethanol, diazepam, cimetidine, ketoconazole (in CYP2D6 extensive and poor metabolizers), indinavir, metoprolol, imipramine, and lithium. The chart compares changes in Cmax (maximum concentration) and AUC (area under the curve) of venlafaxine and its ODV metabolite, with clinical recommendations on concomitant use.*
FDA Label Image

Figure 2: Effect Of Venlafaxine On The Pharmacokinetics Interacting Drugs And Their Active Metabolites. (Venlafaxine Fig2)

Figure 2: Effect Of Venlafaxine On The Pharmacokinetics Interacting Drugs And Their Active Metabolites. (Venlafaxine Fig2)
A forest plot displaying the pharmacokinetic fold change and 90% confidence interval (CI) for various interacting drugs with venlafaxine hydrochloride. The chart shows changes in Cmax and AUC values for several drugs and metabolites, alongside recommendations for dose adjustment or concomitant use. The x-axis represents the change relative to the reference value, ranging from 0 to 3.*
FDA Label Image

Figure 3: Pharmacokinetics Of Venlafaxine And Its Metabolite O-desmethylvenlafaxine (odv) In Special Populations. (Venlafaxine Fig3)

Figure 3: Pharmacokinetics Of Venlafaxine And Its Metabolite O-desmethylvenlafaxine (odv) In Special Populations. (Venlafaxine Fig3)
A chart depicting pharmacokinetic changes and dosage recommendations for Venlafaxine Hydrochloride (75 mg extended-release capsules) in special populations, including hepatic impairment, renal impairment, CYP2D6 polymorphism, age above 60 years, and gender. The chart presents fold changes in Cmax, AUC, and ODV with confidence intervals, alongside recommended dose adjustments for each group.*
FDA Label Image

Chemical Structure (Venlafaxine Str)

Chemical Structure (Venlafaxine Str)
Chemical structure of venlafaxine hydrochloride displaying its molecular framework with labeled functional groups, including a methoxyphenyl ring and a cyclohexanol moiety, associated with the hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.